Literature DB >> 22288590

Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency.

M van Geffen1, M Cugno, P Lap, A Loof, M Cicardi, W van Heerde.   

Abstract

Patients with functional deficiency of C1-inhibitor (C1-INH) suffer from recurrent acute attacks (AA) of localized oedema associated with activation of the contact system, complement and fibrinolysis. To unravel further the role of coagulation and fibrinolysis in the pathophysiology of C1-INH deficiency, we performed simultaneous thrombin and plasmin generation measurements in plasma from patients with hereditary angioedema (HAE) due to C1-INH deficiency during AA (n = 23), in remission (R) (n = 20) and in controls (n = 20). During AA thrombin generation after in-vitro activation of plasma was higher than in controls, as demonstrated by shorter thrombin peak-time (P < 0·05), higher thrombin peak-height (P < 0·001) and increased area under the curve (AUC) (P < 0·05). Additionally, elevated levels of prothrombin fragment 1+2 (P < 0·0001) were observed in non-activated plasma from the same patients. In contrast, in activated plasma from patients during AA plasmin generation estimated as plasmin peak-height (P < 0·05) and plasmin potential (P < 0·05) was reduced, but non-activated plasma of the same patients showed elevated plasmin-anti-plasmin (PAP) complexes (P < 0·001). This apparent discrepancy can be reconciled by elevated soluble thrombomodulin (sTM) (P < 0·01) and thrombin activatable fibrinolysis inhibitor (TAFI) in patients during AA providing possible evidence for a regulatory effect on fibrinolysis. Plasminogen activator inhibitor-1 (PAI-1) was reduced in patients during AA indicating, together with the observed reduction of plasmin generation, the consumption of fibrinolytic factors. In conclusion, our results support the involvement of coagulation and fibrinolysis in the pathophysiology of HAE and show the possible application of simultaneous measurement of thrombin and plasmin generation to evaluate different clinical conditions in HAE patients.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22288590      PMCID: PMC3374279          DOI: 10.1111/j.1365-2249.2011.04541.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin.

Authors:  A Ichinose; K Fujikawa; T Suyama
Journal:  J Biol Chem       Date:  1986-03-15       Impact factor: 5.157

2.  Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study.

Authors:  M M Frank; J S Sergent; M A Kane; D W Alling
Journal:  N Engl J Med       Date:  1972-04-13       Impact factor: 91.245

3.  Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema.

Authors:  M Quastel; R Harrison; M Cicardi; C A Alper; F S Rosen
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

4.  Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.

Authors:  P C Harpel; N R Cooper
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

5.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

6.  Functional and structural similarities between protease nexin I and C1 inhibitor.

Authors:  W E Van Nostrand; L D McKay; J B Baker; D D Cunningham
Journal:  J Biol Chem       Date:  1988-03-15       Impact factor: 5.157

7.  Haemostasis contact system and fibrinolysis in hereditary angioedema (C1-inhibitor deficiency).

Authors:  M Cugno; L Bergamaschini; L Uziel; M Cicardi; A Agostoni; A F Jie; C Kluft
Journal:  J Clin Chem Clin Biochem       Date:  1988-07

8.  Activation of bovine factor VII by hageman factor fragments.

Authors:  R Radcliffe; A Bagdasarian; R Colman; Y Nemerson
Journal:  Blood       Date:  1977-10       Impact factor: 22.113

9.  Thrombin-induced increase in albumin permeability across the endothelium.

Authors:  J G Garcia; A Siflinger-Birnboim; R Bizios; P J Del Vecchio; J W Fenton; A B Malik
Journal:  J Cell Physiol       Date:  1986-07       Impact factor: 6.384

10.  A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

View more
  24 in total

1.  Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels.

Authors:  Kusumam Joseph; Baby G Tholanikunnel; Bethany Wolf; Konrad Bork; Allen P Kaplan
Journal:  J Allergy Clin Immunol       Date:  2015-09-26       Impact factor: 10.793

Review 2.  Chronic Spontaneous Urticaria: The Devil's Itch.

Authors:  Sarbjit S Saini; Allen P Kaplan
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jul - Aug

Review 3.  "Nuts and Bolts" of Laboratory Evaluation of Angioedema.

Authors:  Henriette Farkas; Nóra Veszeli; Erika Kajdácsi; László Cervenak; Lilian Varga
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

Review 4.  Plasminogen Activators in Neurovascular and Neurodegenerative Disorders.

Authors:  Manuel Yepes; Yena Woo; Cynthia Martin-Jimenez
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

5.  Ongoing contact activation in patients with hereditary angioedema.

Authors:  Joke Konings; Massimo Cugno; Chiara Suffritti; Hugo Ten Cate; Marco Cicardi; José W P Govers-Riemslag
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

6.  In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency.

Authors:  A L Manson; A Price; J Dempster; P Clinton-Tarestad; C Greening; R Enti; S Hill; S Grigoriadou; M S Buckland; H J Longhurst
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

Review 7.  The Story of Angioedema: from Quincke to Bradykinin.

Authors:  Avner Reshef; Mona Kidon; Iris Leibovich
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 10.817

8.  Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk.

Authors:  A Reshef; A Zanichelli; H Longhurst; A Relan; C E Hack
Journal:  Allergy       Date:  2015-02-23       Impact factor: 13.146

9.  Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency.

Authors:  Nóra Veszeli; Dorottya Csuka; Zsuzsanna Zotter; Éva Imreh; Mihály Józsi; Szabolcs Benedek; Lilian Varga; Henriette Farkas
Journal:  Orphanet J Rare Dis       Date:  2015-12-10       Impact factor: 4.123

Review 10.  Biomarkers in Hereditary Angioedema.

Authors:  Grzegorz Porebski; Mateusz Kwitniewski; Avner Reshef
Journal:  Clin Rev Allergy Immunol       Date:  2021-02-09       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.